Meeting Announcement
Poster Presentations
Poster Presentations
The Florida Society of Clinical Oncology (FLASCO) encourages FLASCO members to submit an abstract detailing your research endeavors for presentation at the FLASCO Spring & Fall Session. Presenter and research are vetted by the FLASCO Abstract Review Committee. Abstracts of superior quality are selected by the FLASCO Ad Hoc Abstract Committee for presentation at the FLASCO Meetings and for publication on the FLASCO website. The FLASCO Committee strongly encourages the submission of abstracts on research directly influencing the cancer health and outcomes of Floridians.
| Title |
Presenter |
| Long-term outcome of patients with low-grade follicular lymphoma treated with yttrium-90 ibritumomab tiuxetan: The Mayo Clinic experience |
Muhamad Alhaj Moustafa, MD Ricardo D. Parrondo, MD Mayo Clinic Florida |
| CART-Cells Agents and the Post-Marketing Reported Patients Adverse Events Cases | Ollie Annum, PharmD |
| Brianne Dixon, AbbVie | |
|
Alexander E. Perl, MD, University of Pennsylvania Astellas Pharma, Inc. |
|
|
|
Steven L. McCune, MD, PhD Bristol Myers Squibb, Princeton, NJ, USA |
|
|
Firas Badin, M.D. MBA Bristol Myers Squibb, Princeton, NJ, USA |
| Overall survival (OS) for first-line palbociclib (PB) plus letrozole (LE) vs LE alone for HR+/HER2- metastatic breast cancer (MBC) patients in US real-world clinical practice |
Louis Moreno,MD Pfizer Inc |
| Quality of life (QoL) in patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2‒) advanced breast cancer (ABC) treated with palbociclib in real-world practice settings |
Louis Moreno,MD Pfizer Inc |
Exhibitors
Fall Session Exhibitors
- AbbVie Pharmaceuticals
- Adaptive Biotechnologies
- Agios Pharmaceuticals
- Alexion Pharmaceuticals
- Amgen Oncology
- Apellis
- Astellas Pharma
- AstraZeneca
- BeiGene
- Boehringer Ingelheim
- Bristol-Myers Squibb
- BTG International
- Circulogene
- Clovis Oncology
- Coherus Biosciences
- Daiichi Sankyo
- Deciphera
- Dova Pharmaceuticals
- Eisai
- EMD Serono
- Foundation Medicine
- Genentech
- GSK
- Guardant Health
- Heme Onc Call
- Heron Therapeutics
- Immunomedics
- Incyte
- Ipsen Biopharmaceuticals
- Jazz Pharmaceuticals
- Johnson & Johnson
- Karyopharm Therapeutics
- Kite Pharma
- Kyowa Kirin
- Lilly Oncology
- Merck
- Moffitt Cancer Center
- MorphoSys
- Myriad Genetics
- Natera
- NeoGenomics
- Novartis
- Oncology Supply/ION Solutions
- Oncopeptides
- Pfizer Oncology
- Pharmacyclics
- Puma Biotechnology
- Rigel Pharmaceuticals
- Roche Diagnostics
- RxVantage
- Sandoz
- Sanofi Genzyme
- Seattle Genetics
- Servier Pharmaceuticals
- Sun Pharma
- Taiho Oncology
- Takeda Oncology
- Tolmar Pharmaceuticals
- UF Health Cancer Center
Thank you for your support of FLASCO !
Hotel
Gaylord Palms Resort & Convention Center
6000 W. Osceola Parkway, Kissimmee, FL 34746
Continuing Education
In order to receive CME/CE credits for this program:
- You must be registered for the meeting, have signed in at the registration desk (if this is what you are doing onsite) OR if virtual, logged in.
- A link to the evaluation survey will be emailed to you post-program. Please complete this within the allotted time frame.
- Your certificate of attendance will be emailed to you for download immediately after submission.
- Keep the certificate of attendance document for your files.
Evaluation & Certificate of Attendance
In order to receive CME/CE/CPE credits for this program:
Complete and submit the Evaluation Survey which will be emailed to you post-conference. Please complete this within the allotted time frame. Please add @meccinc.com to your contacts to ensure receipt of your evaluation email. For your convenience, you can complete the evaluation using your desktop or mobile device. Your certificate of attendance will be emailed to you for download immediately after submission. Please keep this document for your files.
FLASCO has applied for CE from the Medical Educator Consortium and does not foresee challenges in being approved.
Accreditation and Credit Statements
In support of improving patient care, this activity has been planned and implemented by the Medical Educator Consortium and the Florida Society of Medical Oncology. The Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 3.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physician – The Medical Educator Consortium designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing – The Medical Educator Consortium designates this activity for 3.5 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
Pharmacist – This Application based activity has been approved for 3. contact hours (.9 CEUs) by the Medical Educator Consortium. The Universal Activity Number for this program is JA4008179-9999-20-019-L01-P. Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.
Physician Assistant The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Disclosure Policy – The Medical Educator Consortium (MEC) adheres to the Joint Accreditation Criteria and ACCME Standards for Commercial Support, which requires everyone in a position of controlling the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests related to the activity content. MEC has implemented a mechanism to identify and resolve all conflicts of interest prior to the CME/CE activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity. CME/CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence within the medical profession.
Disclosure of Unlabeled Use – This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.
Disclaimer – Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contradictions and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accredited by 
Power Points & Video Links
Shared PowerPoints
|
A Panel Discussion on Prostate Cancer: What’s New? (Click on names for PP) |
Winston Tan, MD; Jasreman Dhillon, MD; Ephraim Parent, MD, PhD; Eric Brooks, MD; Rohit Bishnoi, MD |
|
COVID-19 Emergency Preparedness |
Jorge Garcia, PharmD, MS, MHA, MBA, FAHE; Alga Ramos Morales, PharmD, BCPS; Jennifer Henry, PharmD; Timothy Gauthier, PharmD |
| Shannon Luker, RN, OCN, CBCN; Ashwin Mehta, MD | |
| Gail Erentreich; Khang Pharm, PharmD; Shelli Johnson | |
| Jose Sandoval-Sus, MD; Michael Jaglal, MD, MS; Tony Kurian, Md | |
| Jorge Garcia, PharmD, MS, MHA, MBA, FACHE; Rebecca Nelson, PharmD | |
| Lisa Nodzon, PhD, ARNP, AOCNP; Lisa Cozzini, APRN | |
|
Lessons Learned from COVID-19 (Click names for PP) |
Vedner Guerrier; Bill Manzie, MBA; Ashwin Mehta, MD; Shelli Johnson; Christy Banach |
| Eva Suarez, MD; Aurelio Castrellon, MD; Nazanin Khakpour, MD; Shahla Masood, MD; Diana Saravia, MD | |
| Immunotherapies HER2+ Targeted Agents (Oral and IV) Update | Anay Moscu, PharmD; BCOP, BCPS; Ryan Janeway, PharmD, BCOP |
|
Hospice: When and how do we begin the conversation? (Click names for PP) |
Lisa Nodzon, PhD, ARNP, AOCNP; Shannon Luker, RN, OCN, CBCN; Lisa Barakat, MSW, LCSW; Amber Thomassen, AGPCNP-BC, AOCNP; Susan Ponder-Stansel |
|
Evidence Based Medicine and Drug Information; How to seek, evaluate, and apply information |
Anay Moscu, PharmD, BCOP, BCPS; Amanda Brahim, PharmD, BCPS, BCOP |
|
It’s Precisely the Time for More Precision in Genomic Testing and Targeted Treatment of NSCLC |
Presented by Mark A. Socinski, MD CME provided by PeerView |
